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ABSTRACT
HIV-1 infection is a serious condition affecting approximately 37 million
individuals. Between 30% and 60% of seropositive individuals will develop symptoms of
clinical depression. These individuals are five times more likely to commit suicide than
non-seropositive clinically depressed patients. Dysfunction in serotonergic and
dopaminergic transmission has consistently been implicated in the pathogenesis of
depression. Specifically, dysfunction in the prefrontal cortex and in the nucleus
accumbens core region have been shown to be underlying factors in the trajectory of
depression. Given these underlying neurological features, the present research employed
behavioral testing and electrochemical recording in an attempt to elucidate the
therapeutic efficacy of the SSRI escitalopram in treating HIV-1 mitigated depressive
symptoms in a transgenic (Tg) rodent model of depression. The HIV-1 Tg rat contains
seven of the nine genes present in the HIV viral genome and presents itself with
impairments similar to those observed in human HIV-1 seropositive individuals. The
HIV-1 Tg rat thus represents a non-infectious model for controlled HIV-1 exposure.
Here, we report failure of the SSRI to attenuate behavioral and electrochemical
alterations present in the HIV-1 Tg rat. Given the known variability of SSRI medication
and previously documented individual differences to drug dosage found within the
model, it is thus concluded that more research is required in order to firmly establish the
global efficacy of escitalopram in treated comorbid HIV-1 clinical depression.
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CHAPTER 1
INTRODUCTION
HIV is a serious condition affecting approximately 37 million people worldwide
as of 2017. Consequently, the condition is estimated to affect roughly 0.8% of adults ages
15-49 (World Health Organization, 2017). In that same year, approximately 37,000 new
cases were estimated to have occurred, many of which remained unknown to affected
individuals (World Health Organization, 2017). While the advent of combination
antiretroviral therapy (cART) has dramatically increased the prospects of living with
HIV, individuals affected still suffer from deficits associated with the condition.
Adherence to cART has the potential to reduce the viral load in the periphery, though the
virus still persists in the central nervous system (Bertrand et al.,2013). HIV is
neuroinvasive and invades the nervous system rapidly after initial exposure, where it
principally infects microglia. The neurovirulent effects of HIV infection often include
neuropathy, dementia, myopathy, and myelopathy (Silvers et al., 2006).
In the United States, an estimated 30-60% of HIV-infected persons will develop
some degree of clinical depression over the course of their lifetime (Bhatia and Munjal,
2014, Castellon et al., 1998). Moreover, the prevalence of suicide among such infected
individuals is three to five times higher than individuals not affected with HIV, despite
treatment for antiretroviral therapy (US Department of Veterans Affairs, 2009). Apathy, a
distinct but highly correlated condition, also remains a common psychiatric disturbance
among HIV infected individuals. This alarming comorbid prevalence is however
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unsurprising given the well-documented relationship between apathy and depression
(Castellon, et al., 1998; Marin, Firinciogullari, and Biedrzycki, 1993). In addition to
depression and apathy, approximately 50% of seropositive individuals will develop some
degree of HIV-associated neurocognitive disorder (HAND) despite adherence to cART.
(Sanmarti, 2014 Bryant et al., 2015).
The development of apathy is attributed directly to the effects of viral infection,
specifically to the consequent expression of the neurotoxic proteins Tat and gp120. These
proteins are hypothesized to produce deleterious effects upon the dopaminergic system
and the neural circuitry underlying reward pathways (McIntosh et al., 2015). The
alarming of degree of dopaminergic dysfunction present during HIV infection has been
extensively documented in both clinical and pre-clinical literature (Aksenov et al., 2008;
Bertrand et al., 2013; Ferris, Mactutus, and Booze, 2008; Fitting et al., 2008; Fitting et
al., 2015; Javadi-Paydar et al., 2017; Nath et al., 2000; Paris et al., 2014; Purohit, Rapaka,
and Shurtleff, 2011; Roscoe, Mactutus and Booze, 2014; Silvers et al., 2006; Zhu et al.,
2009; Denton et al., forthcoming).
The dynamic relationship between HIV-1 and clinical depression has enjoyed
little consideration within the literature, however, as many reports have failed to produce
prospects for any effective treatment regimes. To this end, the present work sought to
examine the effects of treatment with escitalopram to the HIV-1 Transgenic (Tg) rat. The
HIV-1 Tg rat contains 7 of the constituent 9 genes that comprise the HIV viral genome,
resulting in a non-infectious, long-term model of HIV-1 viral protein exposure, which is
an effective model of HIV seropositive individuals adhering to long term cART
treatment. (Reid et al., 2001; Vigorito et al., 2015 McLaurin et al., 2018). The HIV-1 Tg
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rat are produced using an infectious provirus derivation following deletion of the Sph1Bal1 fragment that encompasses the gag and pol genes of the virus, rendering the model
non-infectious. Production of proteins such as the deleterious tat and gp120 remain under
the control of the LTR promoter resulting in protein expression that is thought to
undermine monoamine function (Reid et al., 2001; Bertrand et al., 2018; Denton et al.,
forthcoming).The HIV-1 Tg rat has previously demonstrated compromised
synaptodentric connectivity in the nucleus accumbens core region, in addition to
compromised rates of dopaminergic and serotonergic function in the nucleus accumbens
core and prefrontal cortex, respectively (Roscoe et al., 2014; Denton et al., forthcoming).
Escitalopram is a selective serotonin reuptake inhibitor marketed under the trade
name Lexapro and is commonly prescribed to individuals suffering from depression.
Moreover, the Veteran’s affairs administration considers escitalopram to be a safe
accompaniment to cART therapy (US Department of Veterans Affairs, 2009). Thus, the
present study sought to directly examine the effects of escitalopram treatment upon a
behavioral testing battery comprised of five tasks commonly used to gauge depressive
symptoms in rodent research, followed by examining the real-time release and reuptake
kinetics of serotonin and dopamine as measured by fast-scan cyclic voltammetry (FSCV).
For the present purposes, a five bottle sucrose concentration task, modified hole board
task, elevated plus maze task, pre-pulse inhibition (PPI) of the visual and acoustic startle
task and a social behavior task were used to evaluate the behavioral effects of
escitalopram treatment in HIV-1 Tg versus F344/N rats.
Sucrose preference testing in rodents is used to gauge levels of anhedonia. Rats
naturally consume sweet solutions as a preference over unsweet solutions. Decreased
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consumption of a mixture of sucrose and water relative to consumption of distilled water
alone is a behavioral marker indicative of anhedonic behavior in rodents (Serchov, Calker
and Biber, 2016). Moreover, sucrose preference testing has previously been employed in
studying the HIV-1 Tg rat (Bertrand et al., 2018). Anhedonia is classically considered a
core symptom of clinical depression (Nestler, 2002). The modified hole board task
gauges exploratory behavior – an indication of anxiolytic and depressive symptoms in
rats (Takeda, Tsuji and Matsumiya, 1998). Such symptoms are known to be present if
fewer hole pokes are performed by a rodent relative to age matched control animals.
Nose pokes into the holes of the apparatus are recorded via photocells positioned
underneath the platform. Pre-pulse inhibition of the acoustic and visual startle are
commonly used in depression research in both human and pre-clinical populations (Perry
et al., 2004; Fletcher et al., 2001). Moreover, previous research has demonstrated that the
HIV-1 Tg rat possesses significant deficits in pre-pulse inhibition (Moran et al., 2013;
McLaurin et al., 2017 McLaurin et al., 2018). The elevated plus maze measures
exploratory behavior as a ratio of the time the rodent spends on an open and exposed arm
of the maze versus time spent in closed locations of the maze . Greater time spent in
closed locations of indicative of heightened levels of anxiety and depressive behaviors
(Pellow, et al.,1985). Total time spent in each arm is recorded with behavioral tracking
software. Social interaction is considered to be a measure of anxiety in rodents, and has
previously been employed in antidepressant research (Griebel et al., 1994; Dekeyne et al.,
2000; Rodiguez-Porcel, 2001).
Fast Scan Cyclic Voltammetry (FSCV) is an electrochemical technique that
allows for the rapid detection of a broad range of chemical species. FSCV is a more
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specialized form of cyclic voltammetry in which a considerably higher scan rate is
employed allowing for the rapid acquisition of an individual voltammogram. Thus, the
technique has a considerable temporal resolution. FSCV enjoys a competitive advantage
over other available techniques in that concentration of the target analyte is observed in
real-time, with quantification of the target analyte occurring rapidly. Moreover, positive
identification of the target analyte is provided via the cyclic voltammogram produced
throughout the recording period (Robinson, et. al, 2003).
FSCV involves the application of a triangular waveform within a target analyte
specific voltage range to an electrode. The resting potential is held at a voltage that is
insufficient to oxidize the target analyte, then rapidly increased at a high scan rate to a
target potential to promote oxidation. This oxidation produces a detectable electrical
current. The potential is then returned to starting potential, thus produce a detectable
change in electrical current in the opposite direction. This cycle of oxidation and
reduction produces time-resolved peaks that allow for the quantification of the target
analyte.
The technique was initially developed by Mark Wightman in the 1980’s, and first
used to characterize dopaminergic transmission and reuptake in the caudate nucleus of
the rat (Millar et. al, 1985). Since this initial development, FSCV has enjoyed a wide
range of application to the study of dopaminergic transmission in single cells, brain
slices, anesthetized animals, freely moving animals, and even awake and behaving
animals (Budygin, et. al, 2001; Kelly and Wightman, 1987; Kuhr, Wightman and Rebec,
1987; Millar et al., 1985; Phillips et. al, 2003; Robinson et. al, 2003; Troyer and
Wightman, 2002).

5

While the quantification of dopamine with FSCV enjoyed a long history of
consistent replication, quantification of serotonin did not occur until much more recently.
The first in-vivo recording of 5-hydroxytryptamine (5-HT or serotonin) in the
mammalian brain occurred as recently as 2009 (Hashemi et. al, 2009). This was achieved
through modification to the standard carbon fiber electrode with Nafion, a cation
exchange polymer. While the oxidation of dopamine to dopamine-o-quinone is a
relatively clean and predictable process, the oxidation of serotonin produces by-products
that polymerize and permanently coat the surface of the carbon fiber microelectrode
(Hashemi et. al, 2009). The Nafion coating prevents the by-products of oxidation from
damaging the surface of the electrode (Hashemi et. al, 2009).
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CHAPTER 2
MATERIALS AND METHODS
2.1 ETHICS STATEMENT
Experiments were conducted in accordance with the recommendations listed in
the Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health. The research protocols were approved by the Institutional Animal Care and Use
Committee at the University of South Carolina (assurance number: D16-00028).
2.2 SUBJECTS
Animals (n=73; HIV-1 Tg=31, F344/N=42) were obtained from Envigo,
(Indianapolis, IN) and pair housed under targeted conditions of 21°±2 °C, 50 %±10 %
relative humidity with a 12 hour light: dark cycle.. Animals were pair housed by both sex
and genotype. Food (Pro-Lab Rat, Mouse, and Hamster chow # 3000) and water were
available ad libitum throughout the duration of the experiment. All behavior tasks were
conducted during diurnal hours.
2.3 DRUG TREATMENT
Escitalopram (4 mg/kg for 40 days) (Sigma Aldrich, Saint Louis, MO) or placebo
pellets (Innovative Research of America, Sarasota, FL) were subcutaneously implanted in
the medial neck area of each animal. Animals were anesthetized using a 2-3%
concentration of sevoflurane. Fur was removed from the target area and a small
(approximately 3 mm) incision was made into which the pellet was placed. Incisions
were then sutured and each animal was administered a bodyweight dependent dose of
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butorphanol and placed in a recovery chamber with a heating pad. Animals were returned
to their home cages after full locomotor recovery occurred. Animals were monitored for
one week in post-operative care before beginning behavioral testing. Animal body weight
and well-being were monitored daily to ensure compliance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health.
2.4 ESTROUS CYCLE TRACKING
Vaginal lavage was performed on each day of the testing period to determine
cycle stage of female rodents. Each lavage was performed with approximately 1 mL of
freshly prepared phosphate-buffered solution. The solution was administered to the
vagina of the rat with a standard eye dropper and quickly retracted. The solution was then
evaluated under a low-power light microscope to determine cycle stage (Booze et
al.,1999; Westwood, 2008).
2.5 SUCROSE PREFERENCE
Animals were individually placed in an empty testing chamber with free access to
0%, 1%, 5%, 10% and 30% concentrations of sucrose solution in 100 ml graduated
cylinders equipped with stopper and drinking tube (Ancare, Bellmore, NY). Habituation
to the five bottle presense occurred two consecutive days prior to testing period.
Following habituation, animals were tested for 30 minutes per day for five consecutive
days. Sucrose consumption was measured both with respect to meniscus volume and
cylinder weight. Cylinder order was randomized daily using a Latin square design to
control for any effect of cylinder position upon sucrose consumption.
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2.6 MODIFIED HOLE BOARD
A custom made delrin insert equipped with 16 equidistant holes was placed inside
a 40 cm3 locomotor activity chamber. Nose pokes into each hole was recorded by
photocells placed below the custom insert. Each nose poke was recorded by FlexField
Software (SanDiego Instruments, San Diego CA). Recording sessions occurred for 10
minutes each day for a period of 7 consecutive days following a 10 minute habituation
period. The apparatus was cleaned with a 10% ethanol solution following the testing
period. Testing was performed in the presence of 70db background white noise in a
darkened room to encourage exploratory behavior.
2.7 ELEVATED PLUS MAZE
Each animal received a single testing session in an elevated plus maze apparatus.
Behavior was recorded by a camera mounted above the apparatus. The dependent
measure of interest was time spent in the open arm of the apparatus versus time spent in
the closed arm of the apparatus. Overall activity was recorded with SMART tracking
software (San Diego Instruments, San Diego CA). The apparatus was cleaned with a 10%
ethanol solution between consecutive trials. Female animals were tested while in diestrus
to control for any effect of estrus hormonal cycle upon exploratory animal. Failed trials
(e.g. animal falling from apparatus) were retested one week later. This time in between
trials was used to ensure no effect of learning/habituation upon subsequent plus maze
trials.
2.8 PREPULSE INHIBITION OF ACOUSTIC AND VISUAL STARTLE
Animals were placed in a startle chamber (SR-Lab Startle Reflex System, San
Diego Instruments) enclosed in an isolation cabinet (Industrial Acoustic Company) and
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acclimated to the presence of 70dB background noise for a period of 5 minutes. The
subjects were then presented with a series of six pulse-only trials at 100dB. Following
this acclimation period, subjects were presented with 36 pre-pulse trials of 85dB with
interstimulus intervals of 0, 8, 40, 80, 120 and 4,000 milliseconds assigned in a Latin
square procedure. The stimulus occured for 20 milliseconds. 0 and 4000 millisecond
intervals were included to provide a baseline acoustic startle response. The apparatus was
cleaned thoroughly with ethanol solution between each trial.
2.9 SOCIAL AND PLAY BEHAVIOR
On the day of testing, animals were habituated to the testing room for a period of
10 minutes. Animals were then placed into an empty testing chamber with a bodyweight
and sex matched novel partner. Rodent interaction was recorded for a period of 10
minutes. Total interaction time was recorded as a dependent measure of social behavior.
Females were tested in diestrus. Successive trials were conducted in previously cleaned
cages to account for any bias due to novel smell or debris.
2.10 MANUFACTURE OF CARBON FIBER MICROELECTRODES
Carbon fiber microelectrodes were manufactured by aspirating 7 µm diameter
carbon-fibers (Goodfellow Inc, Coraopolis, PA) into glass capillaries (0.6mm external
diameter, 0.4mm internal diameter, A-M Systems Inc., Sequim, WA). Fibers were sealed
into the capillaries with a vertical pipette puller (Narishige Group, Tokyo, Japan). The
exposed fiber was trimmed to approximately 150 µm under a low-light power
microscope for evaluation of serotonin and histamine and to 50 µm for evaluation of
dopamine. Nafion was electrodeposited onto the exposed carbon fiber portion of
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serotonin and histamine electrodes as previously described and then dried at 70º C for 10
minutes (Hashemi et al. 2009).
2.11 IMPLANTATION OF CARBON FIBER MICROELECTRODES AND
STIMULATING PIN
Animals were deeply anesthetized using 2-4% sevoflurane. The animal’s head
was placed into a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA.), with a
heating pad to maintain constant body temperature. Carbon fiber microelectrodes were
placed into the animal’s nucleus accumbens (AP: +2.6, ML: +1.6, DV: -5.8) and CA2
region of the hippocampus (AP: -5.5, ML: +5.0, DV: -4.0), for evaluation of dopamine
and serotonin, respectively (Paxinos and Watson, 2014). A stainless steel stimulating
electrode (Plastics One, Roanoke VA) was implanted in the medial forebrain bundle (AP:
-2.8, ML: +1.7, DV: -8.0), while a chloride electroplated silver reference electrode was
placed in the hemisphere opposite the stimulating electrode. To stimulate the release of
the neurotransmitters, biphasic pulse trains were applied through a NeuroLog linear
constant current stimulus isolator (NL800A, Neurolog; Medical Systems Corp., Great
Neck, NY). Background-subtracted cyclic voltammograms were obtained as time vs.
voltage (x-axis by y-axis).
2.12 TERMINATION (SACRIFICE) OF ANIMAL
Following the conclusion of the recording session, animals were sacrificed under
deep anesthesia. Brains were removed and stored in a -80ºC freezer. Animals not used for
voltammetry were sacrificed via transcardial perfusion of approximately 100 mL of
freshly prepared paraformaldehyde. Brains were then removed and stored in
paraformaldehyde for further analyses.
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2.13 BEHAVIORAL DATA ANALYSIS
All statistical analyses were performed using IBM SPSS (version 24) where a pvalue of less than 0.05 was considered to be statistically significant. For evaluation of
sucrose preference, a mixed factorial ANOVA was utilized where transgene, sex and
treatment were held as between subject factors while variable concentration of sucrose
was held as a within-subjects factor. Similarly, a mixed factorial ANOVA was used for
evaluation of pre-pulse inhibition where transgene, sex and treatment were held as
between subject factors while variable inter-stimulus interval was held as a withinsubjects factor. To evaluate elevated-plus maze performance and social behavior, a
factorial ANOVA was employed to examine the effects of treatment, sex and transgene.
All graphs were produced with GraphPad prism (version 5). Rodent age was held as a
covariate across all analyses.
2.14 VOLTAMMETRIC DATA ANALYSIS
Recordings were obtained using customized software. LabView (Knowmad
Technologies LLC). Color plots of the evoked chemicals were generated within the data
analysis features of the custom software. GraphPad Prism (version 5) was used to
produce current versus time plots for each neurotransmitter of interest. Peak
concentrations of neurotransmitter release were analyzed using IBM SPSS (version 24)
with a factorial ANOVA comparing factors of the transgene (HIV-1 Tg vs. F344/N) and
sex. P-values less than or equal to 0.05 were considered statistically significant. Rates of
release and reuptake of individual analytes were calculated using GraphPad prism where
K, a nonlinear rate constant, was evaluated for both release and reuptake. Peak
concentration values were obtained from the raw evoked electrical current. Female
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rodents were evaluated during diestrus to control for any bias due to fluctuation of
circulating hormones. All terminal sacrifices of rats were conducted during diestrus in a
similar manner. This procedure was done in order to eliminate sources of variation for
future analyses.
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CHAPTER 3
RESULTS
3.1 SUCROSE PREFERENCE
Escitalopram was not found to alter sucrose consumption in either HIV-1 Tg
animals or F344/N control animals. Linear and non-linear modeling of the response to
concentration curves revealed a transgene mediated alteration of response, with a shift in
response to sucrose concentration occurring in HIV-1 Tg animals independent of drug
treatment. Dose-dependent responding to sucrose concentrations proceeded in a
logarithmic fashion for these animals, while, in contrast, dose-dependent responding in
F344/N control animals proceeded in a linear fashion. Separate models were fit to the
data to illustrate this finding. (All r2>75%). (Figure 3.1).
3.2 MODIFIED HOLE BOARD AND ELEVATED PLUS MAZE
A mixed model ANOVA was used to evaluate the effects of genotype, sex,
treatment and their interactions upon the within-subjects factor of overall exploration
(hole pokes, open arm exploration) (Figures 3.2 and 3.3). A significant interaction was
found for genotype and sex with respect to exploration [F(1,71)=3.59, p≤0.05]. Rats
treated with escitalopram explored significantly more relative to placebo treated animals
across elevated plus maze trials. [F(1,72)=4.21, p≤0.05]. While global effects of
escitalopram treatment were not found across both tasks together, escitalopram
significantly increased exploration in elevated plus maze trials. Males showed the lowest
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response to escitalopram independent of genotype across both trials, though the
effect was not statistically significant [F(1,72)= 1.11, p=ns]
3.3 PREPULSE INHIBITION OF ACOUSTIC AND VISUAL STARTLE
Significant main effects of genotype were reported for both visual (Figure 3.4)
and auditory (Figure 3.5) PPI, with HIV-1 Tg animals demonstrating significant
impairment relative to controls [visual PPI, F(1,72)=12.12, p≤0.01; auditory PPI,
F(1,72)=8.38, p≤0.05]. Although escitalopram treatment did appear to alter both auditory
and visual PPI in transgenic rats, no interaction effects or other main effects were found
to be statistically significant. HIV-1 Tg rats treated with escitalopram demonstrated
significant visual PPI impairments relative to placebo treated animals and F344/N
animals, suggesting a visual effect of chronic escitalopram treatment.
3.4 SOCIAL AND PLAY BEHAVIOR
No significant main effects for between-subjects factors of genotype, sex or drug
treatment. Additionally, no two-way or three way interactions were found [F(1,72)=3.83,
p=ns]. Overall, total time in contact between rodents was stable regardless of sex,
genotype or treatment condition (Figure 3.6).
3.5 DOPAMINE AND SEROTONIN VOLTAMMETRY
Decreases in peak transmission and reuptake of dopamine and serotonin were
found in the HIV-1 Tg rat. Evoked dopamine and serotonin concentrations for HIV-1 Tg
animals and F344 animals are displayed in figures 3.8 and 3.9 while color plots with
respective cyclic voltammograms are displayed in figure 3.7. Maximal evoked
concentration (Cmax) was impaired in transgenic animals across both dopamine and
serotonin recordings. [Dopamine, F(1,9)=33.25, p≤0.001; For serotonin, F(1,16)=60.97,
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p≤0.001]. Additionally, rates of reuptake as defined by nonlinear rate constant (k) were
impaired in transgenic animals relative to control animals. [For dopamine, F344/N
K=0.43, HIV-1Tg K=0.73 F(1,2634)=19.19, p≤0.001; For serotonin, F344/N K=0.37,
HIV-1Tg K=0.56 F(1,4314)=7.308, p≤0.05.
Increases in serotonin transmission were found in F344/N control animals treated
with escitalopram, but not in HIV-1 Tg rodents (Figure 3.9). Rates of clearance
(reuptake) were slower in animals treated with escitalopram (k=0.55) relative to animals
treated with placebo (k=0.34) [F(1,4074)=9.18, p≤0.05]. While F344/N animals treated
with escitalopram displayed a mild increase in peak evoked serotonergic potential, the
effect was not significant [F(1,30)=0.99, p=ns] although rates of reuptake were altered for
animals treated with escitalopram [k=0.32 vs. k=0.20 F(1,7674)=23.75, p≤0.01].
No statistically significant differences were found for dopamine transmission in
HIV-1 Tg rats treated with escitalopram [F(91,150)=1.00, p=ns (Figure 3.8). Evoked
rates of maximal dopamine release were not statistically significant across a genotype by
treatment analysis [F(1,18)=0.123, p=ns.], though HIV-animals treated with SSRI
medication demonstrated lowest peak concentration. Rates of reuptake were not
statistically different for HIV-1 Tg animals treated with escitalopram [(k=0.41
F(1,1414)=0.47, p=ns], though F344/N animals treated with escitalopram demonstrated
slower rates of reuptake than animals treated with the placebo [k=0.49 vs. k=0.23
F(1,3834)=16.1, p≤0.001].
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Figure 3.1: Five bottle sucrose preference test using a 0%, 1%, 5% 10% and 30%
concentration. No effect of drug treatment was observed independent of animal genotype
and sex. For HIV-1 Tg animals, a curvilinear shift in response occurred between 0% and
5% concentrations followed by a flattening of the dose-response curve between
concentrations of 5% and 30%. F344/N animals displayed a steady linear dose response
pattern. Separate models were fit to these data to illustrate this finding (all r2> 0.75).
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Figure 3.2: Modified hole board performance across each treatment group. Animals were
tested in a custom build modified hole board apparatus across seven consecutive testing
periods. Escitalopram was not found to increase number of nose pokes independently of
genotype or sex. Males demonstrated lowest performance overall, though the effect was
not statistically significant.
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Figure 3.3: Exploration time in the open arm of an elevated plus maze apparatus. Animals
were tested during one trial for a period of ten minutes. Escitalopram was found to
increase time spent in the open arm independently of genotype and sex (p<0.05).
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Figure 3.4: Visual prepulse inhibition. Animals were tested during one trial following a
habituation trial which occurred the day before. Significant impairments were found in
HIV-1 Tg animals relative to controls (p<0.05). Escitalopram was not found to attenuate
these deficits, however treatment did appear to alter PPI response in HIV-1 Tg rats.
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Figure 3.5: Auditory prepulse inhibition. Animals were tested during one trial following a
habituation trial which occurred the day before. Significant impairments were found in
HIV-1 Tg animals relative to controls (p<0.05). Similarly to visual PPI, escitalopram was
not found to attenuate these deficits.
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Figure 3.6: Social interaction time. Animals were tested with a novel sex and bodyweight
matched partner in a novel cage across a ten minute trial period. Social interaction time
was not found to be different regardless of group. No deficits in the HIV-1 Tg rat are
present for social interaction time, and escitalopram was not found to alter interaction
time across the trial period.
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Table 3.1
3.1.1 Exploratory Behavior
Genotype
Sex
Treatment
Genotype X Sex
Genotype X Treatment
Sex X Treatment
Genotype X Treatment X Sex
3.1.2 Visual Pre-Pulse inhibition
Genotype
Sex
Treatment
Genotype X Sex
Genotype X Treatment
Sex X Treatment
Genotype X Treatment X Sex
3.1.3 Auditory Pre-Pulse inhibition
Genotype
Sex
Treatment
Genotype X Sex
Genotype X Treatment
Sex X Treatment
Genotype X Treatment X Sex
3.1.4 Social Interaction Time
Genotype
Sex
Treatment
Genotype X Sex
Genotype X Treatment
Sex X Treatment
Genotype X Treatment X Sex

Effect Sizes ( partial ƞ2) for Behavioral
Effects

0.04
0.17
0.56
0.48
0.04
0.15
0.02
0.19
0.03
<0.01
<0.01
<0.01
<0.01
<0.01
0.14
0.04
<0.01
0.02
<0.01
<0.01
<0.01
<0.01
0.02
<0.01
0.02
<0.01
<0.01
0.06
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Figure 3.7: Evoked colorplots and cyclic voltommograms (inlet) for dopamine (left) and
serotonin (right) in F344/N animals (top) and HIV-1 Tg animals (bottom).
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Figure 3.8: Evoked dopaminergic potentials for genotype (top) and genotype by treatment
condition (bottom). Dopamine transmission was found to be impaired in HIV-1 Tg
animals relative to F344 controls (p<0.05). Escitalopram treatment was not found to
attenuate dopaminergic deficits in HIV Tg animals.
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Figure 3.9: Evoked serotonergic potentials for genotype (top) and genotype by treatment
condition (bottom). Serotonergic transmission was found to be impaired in HIV-1 Tg
animals relative to F344 controls (p<0.05). Escitalopram treatment was not found to
attenuate dopaminergic deficits in HIV Tg animals, though treatment did appear to alter
serotonergic function in F344 controls.
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CHAPTER 4
DISCUSSION
Presently, the effects of escitalopram treatment upon the HIV-1 Tg rat were
evaluated with a behavioral testing battery and in-vivo electrochemical analysis.
Globally, escitalopram treatment did not appear to significantly alter behavioral
functioning in the HIV-1 Tg rat. While treatment did indeed increase overall serotonergic
transmission in F344/N controls, this effect was not found with respect to HIV-1 Tg
animals, which persisted to demonstrate impairment despite treatment.
Though escitalopram did not appear to alter sucrose consumption in either HIV-1
Tg or F344/N animals, an interesting curvilinear shift in sucrose concentration
responding occurred in HIV-1 Tg animals. F344/N animals displayed a steady linear
relationship across increasing sucrose concentrations with higher concentrations of
sucrose clearly favored. While sucrose concentrations were clearly preferred over water
in HIV-1 Tg rats, responses to concentrations of 5% sucrose or higher were essentially
flat-lined, with no clear preference for higher concentrations despite drug treatment. This
alteration in responding is a departure from previous findings using the HIV-1 Tg rat.
Indeed, Bertrand (2018) did not find a difference in response to variable sucrose
concentration between F344 and HIV-1 Tg animals.
This departure from previous findings may have several alternative explanations.
First, the curvilinear shift and subsequent flattening of responding in the HIV-1 Tg
animals may potentially be an effect of mediation by escitalopram treatment. Previously,
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Bertrand (2018) did not expose animals to any sort of treatment which might
serve as a mediating factor. Secondly, the present study used a much shorter time period
for testing sucrose preference. Bertrand (2018) utilized a testing period of one hour while
the present experiment used a testing window of 30 minutes. This discrepancy may
potentially explain the difference in findings between these studies, although this is
highly unlikely.
Perhaps the most reasonable explanation for the present findings is that Bertrand
(2018) performed sucrose testing on female rats that were ovariectomized and thus not
subject to hormonal fluctuations. In the present experiment, female rats had intact ovaries
and thus normal hormonal function. While research into the effects of hormonal cycling
upon behavioral testing in rats has been rather sparse, it has been previously found that
estrus cyclicity does indeed influence anxiety related behaviors (D’Souza and Sadananda,
2017) and motivated, goal-driven behaviors (Steiner et al., 1981). It is quite probable that
variation in hormone levels could potentially explain this deviation from previous work.
Indeed, the present finding that sucrose consumption is impaired across variable
concentrations is in line with the previous discussion of apathy in the HIV Tg rat, and fits
with the narrative of apathy and HIV within the clinical literature. Here, we report a
flattening of response curve across increasing sucrose concentrations. HIV-1 Tg rats did
not appear to prefer 30% sucrose concentrations any more than they did 5%
concentrations. These findings are highly suggestive of an apathetic response within the
transgenic rat, as rodents with intact, healthy motivational systems should most clearly
prefer higher sucrose concentrations to lower concentrations, with highest preference
given to the highest concentration. Thus, the present findings strongly support the
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argument for motivational dysregulation in the HIV-1 Tg rat, though treatment with
escitalopram failed to attenuate this motivational dysregulation.
While escitalopram treatment did not appear to performance during the sucrose
preference task, effects of escitalopram treatment are more clearly seen in the exploration
based tasks such as the elevated plus maze. Unsurprisingly, multivariate analysis of
rodent performance across both tasks revealed a significant interaction effect between
genotype and sex. With respect to antidepressant treatment, it would appear across both
tasks that escitalopram did indeed improve measures of exploration in both F344 controls
and in HIV-1 Tg rats. With respect to elevated plus maze trials, total time spent on the
open arms of the apparatus was increased in animals treated with escitalopram. In fact,
exploration time for female HIV-1 Tg animals treated with escitalopram was higher than
total times for each of the other groups. However, it is of note that escitalopram did not
produce such robust effects in male F344 animals, as such animals treated with
escitalopram explored less than their placebo treated counterparts.
Findings from the modified hole board task did not produce such robust effects,
however, as escitalopram treated animals performed less average nose pokes across the
trial period than placebo treated animals, with the exception of female F344 rats. HIV-1
Tg rats treated with escitalopram performed more poorly on the task than placebo treated
HIV-1 Tg animals. Mirroring findings from the elevated plus maze, F344 males treated
with escitalopram showed decreased activity relative to placebo treated F344 males.
While conclusions about the efficacy of escitalopram in improving performance
in exploration based tasks in HIV-1 Tg rats are difficult to draw from these mixed
findings, it is clear that anti-depressant treatment was less effective more males,
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irrespective of genotype. This finding closely mirrors findings from clinical
antidepressant trials, as males typically show decreased receptiveness to antidepressant
treatment relative to females, despite the fact that females are far more at risk for the
development of depression than males (Sramek et al., 2016). While many sex-difference
based studies were performed for older forms of antidepressants, Khan et al., (2005)
examined sex differences in response to SSRI treatment across a variety of SSRIs,
including escitalopram and its r-enantiomer citalopram (tradename Celexa). In this study,
while the authors argue that SSRI treatment is still a viable option for males suffering
from depression, the effectiveness of this medication may be much greater for females
(Khan et al., 2005).
In a 2016 review, Sramek and colleagues summarize many of the studies
reporting sex differences with respect to antidepressant function, while no single
mechanism is responsible for the sex dependent response to antidepressant treatment,
many factors have been proposed. Of particular interest, the age of onset of depression in
females is typically during adolescence and may correspond strongly to the onset of
puberty. Hormonal fluctuations in puberty, menstruation and menopause may potentially
affect the efficacy of treatment in addition to sex-dependent monoamine functioning.
Consequently, interactions between serotonin and estrogen may potentially serve as a
biological basis for variable antidepressant action (Sramek et al., 2016).
In addition to factors previously discussed Sramek and colleagues (2016) discuss
factors such as body fat, weight distribution and consequent liver metabolism rates/drug
clearance rats as underlying the differences between male and female response to
antidepressants. Moreover, sex dependent factors such as plasma volume, enzymatic
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activity, protein levels and gastric activity may underlie sex dependent responses to
antidepressant treatment in addition to sociocultural factors such as adherence (Sramek et
al., 2016). Overall, the present findings of decreased escitalopram efficacy in male rats
independent of genotype appears to be consistent with the clinical narrative.
Here, we report significant impairment of both auditory and visual pre-pulse
inhibition in the HIV-1 Tg rat. These findings follow a consistent narrative within our
laboratory as such deficits in pre-pulse inhibition in the HIV-1 Tg rat have been
consistently reported (Moran et al., 2013; McLaurin et al., 2016; McLaurin et al., 2017;
McLaurin et al., 2017; McLaurin et al., 2018). Although the present study replicates the
body of previous literature, an effect of escitalopram treatment was not found to attenuate
deficits in either auditory or visual PPI for HIV-1 Tg animals. However, abnormal
alterations in PPI across inter-stimulus interval for HIV-1 Tg animals were clearly
observed. The cause for this disturbance remains unclear, although it was been noted in
the clinical literature that escitalopram treatment may induce abnormal visual experiences
which may consequently interfere with visual perception (Lai 2012). Such alteration
might clearly impede performance on a visual based task. However, escitalopram did not
alter visual PPI performance in F344/N males. These effects may be due to individual
variation of response to drug treatment in the HIV-1 Tg rat. Indeed, individual
differences in the HIV-1 Tg in the variation of response to potential therapeutics has
previously been described (McLaurin et al., 2018).
Deficits in pre-pulse inhibition have been previously discussed as a feature of
non-psychotic major depressive disorder (Perry et al., 2004) and described as a function
of serotonergic activity (Fletcher et al., 2001). Patients suffering from depression are
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hypothesized to have impaired circuitry of cortico-striato-pallido-thalamic pathways
which regulate PPI- a feature that is also found in schizophrenic patients (Perry et al.,
2004). Although reductions in PPI are slight in depression compared with psychotic
disorders such as schizophrenia, studies suggest a deficit is indeed present when
compared with healthy control patients (Perry et al., 2004, Matuso et al., 2017). Prepulse inhibition represents a translational way to study serotonergic-based deficits which
likely underlie to high incidence of comorbidity between HIV and depression. However,
the effect of serotonergic agonists upon PPI is understudied and often inconclusive
(Martinez and Geyer, 1997; Phillips et al., 2000; Quednow et al., 2004).
No differences were found in social interaction for any treatment group.
Irrespective of genotype, sex or treatment, rodents typically spent the majority of the trail
period engaged in some form of social interaction. HIV-1 Tg animals displayed no
impairment in social interaction compared to controls. These findings are in line with
previous work, given the context of what is known about the relatively healthy growth
and progression of the HIV-1 Tg rat across its lifespan. No aberrations have been
reported in healthy growth weight for the HIV-1 Tg rat (Peng et al., 2010; Moran et al.,
2013). Moreover, across several studies, the HIV-1 Tg rat has repeatedly exhibited intact
sensory and motor function (Peng et al., 2010; McLaurin et al.,2018). Taken together,
nothing about what is known about the relatively healthy growth and function of the
transgenic rat would suggest a deficit in social interaction.
Anti-depressant treatment is generally understood to produce anxiolytic properties
in both preclinical (Griebel et al., 1994) and clinical studies (Kent et al., 1998). Despite
this understanding, previous literature has shown r-citalopram (Lexapro) to actually
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decrease social interaction in rodent models (Dekeyne et al., 2000 Rodriguez-Porcel et
al., 2011). Despite the findings of these studies, here we report no global effect of
escitalopram upon social interaction time. A potential explanation for these findings is
that in the present study, antidepressant treatment was chronically administered to
animals with healthy social interaction systems. As previously discussed, no prior
literature provides an evidentiary basis for why any social impairment would exist in the
HIV-1 Tg rat. Previous experiments in which antidepressant treatment was found to
increase social interaction were conducted in animals which had interaction activities
disrupted by procedures such as social defeat (Griebel et al., 1994). Studies which
reported r-citalopram as decreasing social interaction administered the treatment to
animals either as an acute dosage (Dekeyne et al., 2000) or in neonates (Rodriguez-Porcel
et al., 2011). In the case of acute dosages, it is possible that an immediate increase in
serotonin levels would elicit adverse effects upon initial administration (Mir and Taylor
1997; Dekeyne et al., 2000). Moreover, such acute high doses may potentially result in a
loss of serotonin selectivity, and incorporate adrenergic and dopaminergic transmission,
thereby producing an initial increase in anxiety behaviors (Dekeyne et al., 2000). Given
that the present study utilized a chronic treatment protocol in adult rodents unlikely to
have prior social impairment as a function of intervention such as social defeat, the
present findings of no effects of escitalopram upon social interaction are unsurprising.
Here, we report simultaneous decreases in rates of release and reuptake in
dopamine and serotonin activity in HIV-1 Tg rats relative to F344/N controls, which has
previously been described by our lab (Denton et al, forthcoming). For both
neurotransmitters, HIV-1 Tg animals demonstrated impaired release kinetics coupled
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with a significantly decreased maximal release (Cmax). Moreover, reuptake rates in the
HIV-1 Tg rat were significantly impaired relative to controls for both dopamine and
serotonin. Transgene mitigated impairments in serotonin and dopamine function may
provide a neurological basis for comorbid HIV-1 and clinical depression/apathy.
The current findings of dopaminergic impairments in the HIV-1 Tg rat are
consistent with our previous research (Javadi-Paydar et al. 2017), which examined
reuptake times for DA in the HIV-1 Tg rat using ex vivo striatal brain slices. A marked
extension in reuptake time for exogenously applied DA was found in the HIV-1 Tg brain
slices, relative to F344/N slices, further suggesting a role of DAT dysfunction in
mediating DA kinetics in the HIV-1 Tg rat. Moreover, the present findings are consistent
with what was reported by Denton et al., (forthcoming), which demonstrated profound
dysfunction of dopamine and serotonin transmission in the HIV-1 Tg rat using an
identical FSCV protocol as what is described here. In vitro, the HIV-1 protein Tat inhibits
vesicular monoamine transporter (VMAT2) function (Midde et al. 2012). VMAT2 plays
an essential role in the packaging of dopamine and serotonin into synaptic vesicles for
later release (Caudle et. al 2007, Eiden and Weihe 2011). Thus, a disruption in
monoamine synthesis and packaging may play a role in present findings of dopamine and
serotonergic impairments in the HIV-1 Tg rat.
Dopaminergic functioning in the HIV-1 Tg rat following long-term HIV-1 protein
exposure is characterized by decreased release, lower peak concentrations, and slowed
reuptake, which are consistent with in vivo PET imaging studies of the HIV-1 Tg rat
(Sinharay et al. 2017) and findings in human HIV-1 PET imaging studies (Chang et al.
2008). In contrast, prior studies using synaptosomal preparations from HIV-1 Tg rats

34

(Zhu et al. 2016; Bertrand et al. 2018) reported increased DA reuptake rates. The
increased efficiency of synaptosomal DAT function in HIV-1 Tg rats likely reflects a
compensatory response in surviving synapses to long-term HIV-1 protein exposure.
Long-term HIV-1 protein exposure (many months to years in the HIV-1 Tg rat, i.e.,
similar to long-term HIV-1 exposure in humans) decreases dopaminergic circuit
neurotransmission, despite maximal DAT function.
The repeated finding that cortical serotonergic function is disrupted in the HIV-1
transgenic rat provides a potential biological basis for the high comorbidity instances of
HIV-1 and clinical depression in the human population. An estimated 30-60% of HIV-1infected persons in the United States will develop symptoms of clinical depression over
the course of their lifetime (Bhatia and Munjal 2014, Castellon et al. 1998). Given our
consistent findings of diminished serotonin in the HIV-1 Tg rat and the high rates of
comorbidity of HIV-1 and depression in the clinical population, a serotonergic treatment
is a logical candidate to be an effective therapeutic for individuals suffering from
comorbid HIV and depression. Indeed, in a 2018 meta-analysis, Eschun-Wilson and
colleagues found that antidepressant therapy was more effective than placebo treatment
in combating depression across a sample of ten studies. While the authors acknowledge
this trend, they emphasize that the available evidence is limited and sparse (EschunWilson et al. 2018). However, before such efficacy can be reliably demonstrated, there is
a clear need for more mechanistic studies of monoamines in animal models of HIV-1 and
in the seropositive clinical population.
Presently, escitalopram treatment was not found to attenuate dopaminergic or
serotonergic impairment in HIV-1 Tg rats, nor did it alter dopaminergic tone in F344/N
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rats. However, serotonin functioning in F/344 animals was improved by escitalopram
treatment, though the effect fell short of statistical significance. Treatment failed to even
marginally improve serotonergic functioning in HIV-1 Tg animals. These findings
suggest that proper pharmacological intervention my necessitate an individual differences
based approach. Indeed, McLaurin (2018) argues the importance in assessing the
individual differences that occur as a function of heterogeneity within the HIV-1 Tg rat
when exploring potential treatment avenues. Given that the present findings reveal that
escitalopram did not improve serotonergic tone in the HIV-1 Tg rat, but increased
transmission in control rats, perhaps a similar individual differences based approach is
warranted when exploring potential therapeutics for comorbid HIV and depression.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
The present study examined the therapeutic efficacy of the SSRI antidepressant
escitalopram in attenuating HIV-1 mitigated deficits in the HIV-1 Tg rat. Each of these
deficits presents a strong clinical correlate to typical observations among HIV-1 patients
suffering from comorbid clinical depression. Overall, escitalopram was not found to
attenuate alterations in motivational response, pre-pulse inhibition or social behavior in
the HIV-1 Tg rat. Escitalopram did, however, modulated exploratory based behaviors.
Voltammetric analysis revealed that while escitalopram did indeed alter serotonergic
function globally, it did not appear to alter transgene mediated deficits in either
serotonergic or dopaminergic functioning. Thus, preliminary investigations yield little
evidence in support of escitalopram as an effective therapeutic for HIV-1 comorbid
depression. This is unsurprising given what is known about the widely variable nature of
antidepressant action.
Given what is known about individual response to drug treatment in the HIV-1 Tg
rat, future efforts will be targeted toward developing more conclusive statistical models
that will be able to further elucidate the actions of escitalopram within the transgenic rat
at an individual level. SSRI medication is known to have a highly variable range of
efficacy with many factors contributing to its global function. Through analysis of
individual variation and response to escitalopram in the HIV-1 Tg rat, targeted
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therapeutics for HIV-1 seropositive patients suffering from comorbid clinical
depression may perhaps be developed to attenuate depressive symptoms and hopefully
restore normal emotive regulation. These treatments, in combination with adherence to
cART treatment, will hopefully serve to improve overall quality of life for individuals
suffering from HIV in the post-cART era. While developments in the efficacy of
antiretroviral treatment have indeed served to increase the prospects of living with HIV,
significant impairments such as HIV associated neurocognitive disorders and clinical
depression continue to impede the prospects of living with the disease, thus necessitating
the need for targeted therapeutics to treat those symptoms which remain present
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